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The insulin receptor substrate (IRS) proteins serve as essen-
tial signaling intermediates for the activation of PI3K by both
the insulin-like growth factor 1 receptor (IGF-1R) and its close
family member, the insulin receptor (IR). Although IRS-1 and
IRS-2 share significant homology, they regulate distinct cellular
responses downstream of these receptors and play divergent
roles in breast cancer. To investigate the mechanism by which
signaling through IRS-1 and IRS-2 results in differential out-
comes, we assessed the involvement of the microtubule cyto-
skeleton in IRS-dependent signaling. Treatmentwith drugs that
either stabilize or disrupt microtubules reveal that an intact
microtubule cytoskeleton contributes to IRS-2- but not IRS-1-
mediated activation of AKT by IGF-1. Proximal IGF-1R signal-
ing events, including IRS tyrosine phosphorylation and recruit-
ment of PI3K, are not inhibited by microtubule disruption,
indicating that IRS-2 requires the microtubule cytoskeleton at
the level of downstreameffector activation. IRS-2 colocalization
with tubulin is enhanceduponTaxol-mediatedmicrotubule sta-
bilization, which, together with the signaling data, suggests that
the microtubule cytoskeleton may facilitate access of IRS-2 to
downstream effectors such as AKT. Of clinical relevance is that
our data reveal that expression of IRS-2 sensitizes breast carci-
noma cells to apoptosis in response to treatment with microtu-
bule-disrupting drugs, identifying IRS-2 as a potential bio-
marker for the response of breast cancer patients to Vinca
alkaloid drug treatment.
Insulin receptor substrate 1 (IRS-1)2 and IRS-2 are cytoplas-
mic adaptors for the insulin receptor (IR) and insulin-like
growth factor 1 receptor (IGF-1R), and they play amajor role in
determining the cellular response to stimulation of these recep-
tors (1). Notably, the IRS proteins are required for the activa-
tion of PI3K downstream of the IR and IGF-1R, which activate
AKT andmechanistic target of rapamycin (mTOR) to promote
proliferation, survival, motility, protein synthesis, and glucose
metabolism (2–5). IRS-1 and IRS-2 are expressed ubiquitously
in humans, including in the normal and malignant mammary
epithelium (1). Despite their considerable sequence homology,
IRS-1 and IRS-2 play divergent roles in breast cancer. In vitro,
studies to assess IGF-1-dependent signaling through the IRS
proteins in breast carcinoma cells have revealed that IRS-1 pri-
marily regulates proliferation and survival, whereas IRS-2 reg-
ulates motility, invasion, and glycolysis (6–10). In vivo, overex-
pression of either IRS-1 or IRS-2 in the mouse mammary gland
promotes mammary tumorigenesis (11). However, metastasis
is diminished in the absence of Irs-2 expression and increased
in the absence of Irs-1 expression (9, 12).
Differential localization patterns of IRS-1 and IRS-2 in
human breast tumors suggest one explanation for their diver-
gent functions in breast cancer (13). In normal breast tissue,
ductal carcinoma in situ, and invasive breast tumors, IRS-1 is
primarily localized in the nucleus and also diffusely in the cyto-
plasm, frequently correlating with nuclear expression of estro-
gen receptor (14–16). Nuclear expression of IRS-1 also corre-
lates with response to tamoxifen in breast cancer patients (17).
IRS-1 has been implicated in the regulation of estrogen
response genes through its interaction with the estrogen recep-
tor at estrogen response elements in gene promoters (16). The
interaction of IRS-1 with -catenin and its regulation of genes
such as c-Myc and Cyclin D1 likely contribute to its role in
stimulating proliferation (18, 19). In contrast to IRS-1, IRS-2 is
absent from the nucleus in normal breast and breast tumors
and is expressed either in the cytoplasmor at the cellmembrane
(13). Diffuse cytoplasmic IRS-2 staining is associated with bet-
ter overall survival of breast cancer patients, whereas mem-
brane localization of IRS-2 in breast tumors is associated with
decreased overall survival, particularly in patients with proges-
terone receptor-negative tumors (13).
The localization pattern of IRS-1 and IRS-2 in human tumors
suggests that their trafficking to distinct subcellular compart-
This work was supported by National Institutes of Health Grant CA142782
(to L. M. S.), National Institutes of Health F31 Predoctoral Fellowship
CA180706 (to J. M. M.), and Department of Defense Breast Cancer Predoc-
toral Fellowship W81XWH-10-1-0038 (to J. L. C.). The authors declare that
they have no conflicts of interest with the contents of this article. The con-
tent is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
This article contains supplemental Fig. 1.
1 To whom correspondence should be addressed: Dept. of Molecular, Cell,
and Cancer Biology, University ofMassachusettsMedical School, 364 Plan-
tation St., LRB 409, Worcester, MA 01605. Tel.: 508-856-8675; Fax: 508-856-
1310; E-mail: leslie.shaw@umassmed.edu.
2 The abbreviations used are: IRS, insulin receptor substrate; IR, insulin recep-
tor; IGF, insulin-like growth factor.
cros
ARTICLE
7806 J. Biol. Chem. (2017) 292(19) 7806–7816
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on Septem
ber 25, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on Septem
ber 25, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on Septem
ber 25, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ments contributes to their ability to elicit unique signaling
responses. However, the mechanism by which the intracellular
localization of IRS-1 and IRS-2 is determined is not known. The
microtubule cytoskeleton, which plays an important role in
intracellular trafficking, has been implicated in insulin-depen-
dent regulation of glucose uptake, and this role for microtu-
bules occurs distal to IRS phosphorylation (20–22). These
observations support a role for microtubules in IRS-mediated
downstream signaling, potentially through targeting of these
adaptor proteins to unique subcellular compartments. We
examined the role of themicrotubule cytoskeleton in determin-
ing differential signaling and functional outcomes for IRS-1 and
IRS-2. The data we obtained in this study reveal that IRS-2
co-localizes with microtubules and that the microtubule cyto-
skeleton contributes to IRS-2- but not IRS-1-dependent signal-
ing to AKT. The differential involvement of the microtubule
cytoskeleton in IRS-1- and IRS-2-mediated AKT signaling
influences the apoptotic sensitivity of breast carcinoma cells to
microtubule-disrupting drugs.
Results
IGF-1R signaling is dependent on themicrotubule
cytoskeleton
To investigate the role of the microtubule cytoskeleton in
IRS-dependent IGF-1R signaling, MDA-MB-231 cells were
stimulated with IGF-1 after short-term (30 min to 1 h) treat-
ment with paclitaxel (Taxol) or nocodazole. Taxol, a taxane
drug commonly used in cancer treatment, stabilizes microtu-
bules, whereas nocodazole causes depolymerization of the
tubulin cytoskeleton (23–25). IRS signaling was measured by
assessing the phosphorylation status of AKT, a downstream
signaling effector of PI3K, because the IRS proteins are required
for the recruitment and activation of PI3K by the IGF-1R (4, 5,
26). Althoughmicrotubule stabilization by Taxol treatment did
not alter the level of AKT activation (Fig. 1A), disruption of the
microtubule cytoskeleton in response to nocodazole treatment
significantly reduced phosphorylation of AKT at both threo-
nine 308 and serine 473 (Fig. 1B). In contrast, the activation of
ERK1/2 by IGF-1, which can occur independently of the IRS
proteins (5), was not decreased by nocodazole treatment (Fig.
1B). IGF-1-dependent AKT activation was also reduced when
cells were treated with the Vinca alkaloid drug vinblastine,
which also disruptsmicrotubules and is used clinically in chem-
otherapy regimens (Fig. 1C) (23). Taken together, these results
indicate that an intact microtubule cytoskeleton contributes to
IRS-dependent activation of AKT by the IGF-1R.
To investigate the mechanism by which nocodazole inhibits
AKT activation, phosphorylation of the IGF-1R and IRS pro-
teins and IRS/PI3K associationwere examined. Treatmentwith
nocodazole did not decrease IRS-1 or IRS-2 tyrosine phosphor-
ylation or associationwith the p85 regulatory subunit of PI3K in
response to IGF-1 stimulation, indicating that activation of
Figure 1. Involvement of the microtubule cytoskeleton in IGF-1-stimulated AKT activation.MDA-MB-231 cells were treated with DMSO, Taxol (20 M),
nocodazole (1 M), or vinblastine (20 nM) for 30 min and then stimulated with IGF-1 (20 ng/ml) for 5 min. A—C, aliquots of cell extracts containing equivalent
amounts of total protein were immunoblotted with antibodies specific for Ser(P)-473AKT (pAKT S473), Thr(P)-308AKT (pAKT T308), or Thr(P)-202/Tyr-204ERK
(pERK). The immunoblots were subsequently stripped and reprobed with total AKT and ERK-specific antibodies. D, aliquots of cell extracts containing equiv-
alent amounts of total protein were immunoprecipitated (IP) with antibodies specific for IRS1, IRS2, or IGF-1R subunit and immunoblotted with antibodies
specific for phosphotyrosine (pTyr) and the p85 subunit of PI3K (p85). The Tyr(P) immunoblots were subsequently stripped and reprobed with IRS1, IRS2, or
IGF-1R-specific antibodies. Total cell extracts were also immunoblotted with antibodies specific for Ser(P)-473AKT and total AKT (whole-cell lysate (WCL),
bottom panels). All immunoblots shown are representative of three independent experiments.
IRS2 signaling to AKT involvesmicrotubules
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PI3K upstream of AKT was not inhibited by microtubule dis-
ruption (Fig. 1D). Of note, expression of the IGF-1R  subunit
and its IGF-1-dependent tyrosine phosphorylation were
increased following nocodazole treatment (Fig. 1D). We attrib-
ute this increase to the accumulation of the activated receptor
at the cell surface or in early endosomes, resulting in sustained
expression and activation (27).
IRS-2, but not IRS-1, requires themicrotubule cytoskeleton to
activate AKT
To determine whether there is a selective role for the micro-
tubule cytoskeleton in IRS-1- or IRS-2-mediated signaling,
mammary tumor cells derived from PyMT:WT, PyMT:Irs-
1/, or PyMT:Irs-2/ tumors were treated with nocodazole
and stimulated with IGF-1 (Fig. 2A).WT cells that express both
Irs-1 and Irs-2 demonstrated a 40% reduction in Akt activation
after treatment with nocodazole. PyMT:Irs-1/ cells, which
signal exclusively through Irs-2, exhibited a further reduction
in IGF-1-dependent Akt activation (50%) following treat-
ment with nocodazole. In contrast, Akt activation was equiva-
lent in PyMT:Irs-2/ cells, which signal exclusively through
Irs-1, in response to IGF-1 stimulation following DMSO or
nocodazole treatment.
The role of IRS-2 in the sensitivity of cells to microtubule
disruption was explored further using PyMT:Irs-1/ and
PyMT:Irs-2/ cells that were derived from PyMT:Irs-1fl/fl and
PyMT:Irs-2fl/fl cell lines, respectively, after acute adenoviral-
Cre infection. PyMT:Irs-2fl/fl cells with or without restored
IRS-2 expression were stimulated with IGF-1 after treatment
with nocodazole and vinblastine. An additional Vinca alkaloid
drug, vinorelbine, which is used to treat breast cancer patients
(23, 28), was also assayed (29). As observed previously (Fig. 2A),
disruption of microtubules did not decrease Akt activation in
cells lacking Irs-2 expression (Irs2/), whereas the increase in
Akt activation that was observed upon restoration of IRS-2
expression was eliminated by microtubule disruption (Irs2/:
IRS2) (Fig. 2B). In contrast, the -fold change reduction in Akt
activation observed in Irs1/ cells after nocodazole treatment
(50%) was diminished (30%) upon restoration of IRS-1 expres-
sion (Irs/:IRS1) (Fig. 2C). Taxol treatment did not inhibitAkt
activation in mouse mammary tumor cells (Fig. 2C), as was
observed for MDA-MB-231 cells (Fig. 1A).
To assess the role of microtubules in IRS-2-mediated signal-
ing in human breast carcinoma cells, IRS2 expression was sup-
pressed by shRNA targeting in MDA-MB-231 cells (Fig. 2D).
Total AKT activation in response to IGF-1 stimulation was
reduced in shIRS-2 cells compared with shGFP cells (Fig. 2D,
second and sixth lanes). Treatment of shGFP cells with either
nocodazole or vinblastine significantly reduced AKT activation
(Fig. 2D, third and fourth lanes), as was observed for the paren-
tal cells (Fig. 1C). In contrast, no significant reduction in AKT
phosphorylation occurred in the shIRS2 cells, which signal pre-
dominantly through IRS-1, upon treatmentwith either nocoda-
zole or vinblastine (Fig. 2D, seventh and eighth lanes). The -fold
difference in AKT activation observed in shGFP and shIRS2
cells upon microtubule disruption increased with time of stim-
ulation, indicating that microtubules are required to sustain
IRS2-dependent signaling (Fig. 2E). Taken together with the
mouse cell line data, these results support the hypothesis that
an intactmicrotubule cytoskeleton contributes to IGF-1 signal-
ing through IRS-2 but not IRS-1.
The dependence of IRS2 signaling to Akt on an intact micro-
tubule cytoskeleton indicates a potential interaction of IRS-2
with microtubules. To investigate this possibility, the localiza-
tion of IRS-1, IRS-2, and tubulin was examined by immunoflu-
orescent staining and confocal imaging. For these experiments,
SUM-159 breast carcinoma cells were used because they
express both IRS-1 and IRS-2, spread well on coverslips, and
retain their spreadmorphology upon treatment with Taxol and
nocodazole, which facilitates detection of co-localization. Both
IRS-1 and IRS-2 were expressed in a punctatemanner through-
out the cytoplasm, with a modest enhancement in the perinu-
clear region (Fig. 3; left panels). Although no specific pattern of
staining was observed for IRS-1, the punctate staining for IRS-2
was more organized, with some apparent alignment along
microtubules. To assess further the association of IRS-2 with
microtubules, cells were stained after short-term incubation
with either Taxol or nocodazole to evaluate their impact on IRS
localization. The organized, linear pattern of IRS-2 stainingwas
more apparent upon Taxol stabilization of the microtubules,
and a subset of IRS-2 puncta co-localized with tubulin under
these conditions (Fig. 3B, center panels). IRS-2 was dispersed
throughout the cytoplasmwith no tubulin co-localization upon
disruption of microtubules by nocodazole (Fig. 3B, right pan-
els). In contrast, IRS-1 staining was not modified in response to
Taxol or nocodazole treatment (Fig. 3A).
IRS-2 determines the cellular response tomicrotubule
disruption
Drugs that target themicrotubule cytoskeleton are used clin-
ically for the treatment of cancer (23). To investigate how IRS-2
may impact the response of tumors to microtubule-stabilizing
or -disrupting drugs, MDA-MB-231 cells were treated for 48 h
with either nocodazole or Taxol and then analyzed for viability
by propidium iodide staining and flow cytometry analysis. A
significant increase in the sub-G1 population occurred in
response to both nocodazole and Taxol treatment in shGFP
control cells (Fig. 4A), consistent with an induction of cell
death. Compared with shGFP cells, cell death was significantly
diminished in shIRS-2 cells in response to nocodazole treat-
ment (Fig. 4A). In contrast, when cells were treated with Taxol,
which does not inhibit IRS2-mediated AKT signaling (Figs. 1A
and 2C), cell death levels were similar for shGFP and shIRS2
cells. To further investigate the clinical relevance of the IRS2-
dependent sensitivity of breast carcinoma cells to microtubule
disruption, MDA-MB-231 cells were treated with vinblastine
or vinorelbine, both of which are used in the treatment of solid
tumors, including breast cancer (23). As was observed for
nocodazole treatment, cell death was significantly diminished
in shIRS2 cells treated with either vinblastine or vinorelbine
compared with shGFP-treated cells (Fig. 4B).
A similar resistance to cell death upon treatment with
nocodazole was observed for PyMT:Irs2/ cells compared
with parental cells (PyMT:Irs2fl/fl) or Irs2/ cells in whichWT
Irs-2 expression was restored (Irs2/:IRS2) (Fig. 5A). In con-
trast, restoration of IRS1 expression to PyMT:Irs1/ cells
IRS2 signaling to AKT involvesmicrotubules
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reduced cell death in response to nocodazole treatment (Fig.
5B). Similar to MDA-MB-231 cells, cell death in response to
Taxol treatment was not dependent upon Irs expression in
PyMT mammary tumor cells (Fig. 5, A and B).
As has been reported previously, cells undergo a G2/M arrest
in response tomicrotubule disruption or stabilization (30). The
cell cycle profiles of cells treatedwith nocodazole or Taxol were
analyzed to determine whether IRS2 expression influences the
cell cycle response to microtubule-targeting drugs. MDA-MB-
231:shGFP cells exhibited an increase in G2/M arrest when
treated with nocodazole (Fig. 4C). In contrast, a significantly
higher percentage of MDA-MB-231:shIRS2 cells remained in
Figure 2. Selective requirement of themicrotubule cytoskeleton for IRS-2-mediated signaling.A, PyMT:WT, PyMT:Irs-1/ and PyMT:Irs-2/ cellswere treated
withDMSOor20Mnocodazole (Noc) for1hand thenstimulatedwith IGF-1 (10ng/ml) for5min.B,PyMT:Irs-2/ cells transfectedwithemptyvector (Irs2/) or IRS2
(Irs2/:IRS2)weretreatedwithDMSO,1Mnocodazole,20nMvinblastine(Vin),or20nMvinorelbine(Vino) for1handthenstimulatedwith IGF-1(10ng/ml) for15min.
C, PyMT:Irs-1/ cells transfected with empty vector (Irs1/) or IRS1 (Irs1/:IRS1) were treated with DMSO, 1 M nocodazole, or 10 M Taxol for 1 h and then
stimulated with IGF-1 (10 ng/ml) for 5 min. D, MDA-MB-231 cells expressing either an shRNA targeting GFP (shGFP) or IRS2 (shIRS2) were treated with DMSO, 1 M
nocodazole,or20nMvinblastinefor30minandthenstimulatedwith IGF-1 (10ng/ml) for30min.E,MDA-MB-231cellsexpressingeitheranshRNAtargetingGFPor IRS2
were treatedwithDMSOor 1Mnocodazole for 30min and then stimulatedwith IGF-1 (10ng/ml) for the timeperiods indicated. Thedata in thegraph represent the
-foldchange inphospho-AKTbetweenDMSO-andnocodazole-treatedcells for eachcell type.Aliquotsof cell extracts containingequivalent amountsof totalprotein
were immunoblottedwithantibodiesspecific for IRS1, IRS2,Ser(P)-473AKT, totalAKT, tubulin,orGAPDH.Thedatashowninthegraphsforeach immunoblot represent
themean S.E. of three independent experiments. *, p 0.05 relative to shGFP; **, p 0.01 relative to shGFP.
IRS2 signaling to AKT involvesmicrotubules
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G1/G0 upon disruption ofmicrotubules (Fig. 4D). This increase
in G1/G0 cells was also observed in PyMT:Irs2/ cells (Fig.
5D), and rescue of IRS-2 expression restored the G2/M arrest
profile to that of the parental PyMT:Irs2fl/fl cells (Fig. 5, C and
E). In contrast, PyMT:Irs1/ cells exhibited G2/M arrest, and
restoration of IRS-1 expression promoted an increase in G1/G0
cells (Fig. 5, F andG), similar to the profile of the IRS2-deficient
cells that signal only through IRS1. All cells treated with Taxol
exhibited a similar G2/M arrest profile (Figs. 4 and 5). These
data indicate that breast carcinoma cells that express and signal
through IRS-2 are more sensitive to drugs that depolymerize
microtubules and respond by undergoing cell cycle arrest and
increased cell death, whereas the Taxol response is not deter-
mined by IRS-2 expression.
Given that AKT signaling is selectively resistant to microtu-
bule disruption in cells deficient for IRS2 expression, we
hypothesized that the resistance of these cells to nocodazole-
mediated cell deathwas the result of sustainedAKT signaling in
these cells. To test this hypothesis, cells were treated with
nocodazole for 48 h in the presence or absence of an AKT-
specific inhibitor, MK2206. Treatment of MDA-MB-231
shGFP and shIRS2 cells with MK2206 alone did not alter the
percentage of sub-G1 cells (Fig. 6A) or cell cycle profile (Fig. 6,B
andC), as has been reported previously for parentalMDA-MB-
231 cells at the concentration of inhibitor used in these assays
(28). This concentration ofMK2206 was, however, sufficient to
inhibit AKT activation (Fig. 6D). Combined treatment of the
MDA-MB-231:shGFP cells with MK2206 and nocodazole did
not increase cell death (Fig. 6A) or alter cell cycle progression
(Fig. 6B). In contrast, addition of MK2206 to the nocodazole-
treatedMDA-MB-231:shIRS2 cells increased the percentage of
sub-G1 cells to that observed for shGFP cells treated with
nocodazole alone (Fig. 6A). Combined treatment withMK2206
and nocodazole also promoted G2/M arrest in these cells,
restoring the cell cycle profile to that of the nocodazole-treated,
IRS2-expressing cells (Fig. 6C).
To investigate the mechanism of cell death in response to
microtubule disruption, cell extracts from MDA-MB-231 cells
treated with nocodazole for 48 h in the presence or absence of
MK2206 were immunoblotted for cleaved caspase 3. Caspase 3
cleavage increased significantly upon treatment of shGFP cells
with nocodazole, confirming that these cells undergo apoptotic
cell death (Fig. 7A) (31). Cleaved caspase 3 levels were signifi-
cantly lower in shIRS2 nocodazole-treated cells. However,
combined treatment of shIRS2 cells with both nocodazole and
MK2206 increased caspase 3 cleavage, supporting a role for
AKT signaling in the enhanced viability of these cells. Analysis
of upstream apoptotic effectors identified the BCL2 homology
3 (BH3)-only protein BIM as a potential regulator of caspase 3
activation in response to microtubule disruption (31). Specifi-
cally, the BIM-EL and BIM-L isoforms of BIM were expressed
at elevated levels in shGFP cells compared with shIRS2 cells,
and expression increased upon co-treatment with MK2206 in
shIRS2 cells (Fig. 7B).
Discussion
In this study, we demonstrate a differential involvement of
the microtubule cytoskeleton in IRS-dependent activation of
AKT. AKT activation in response to IGF-1 stimulation ismain-
tained when the microtubule cytoskeleton is disrupted in cells
that signal only through IRS-1. In contrast,microtubule disrup-
tion significantly diminishes AKT activation when the IGF-
1R signals through IRS-2. Proximal IGF-1R signaling events,
includingreceptor tyrosinephosphorylation, IRS tyrosinephos-
phorylation, and recruitment of PI3K, are not inhibited by
microtubule disruption, indicating that IRS-2 requires the
microtubule cytoskeleton at the level of downstream effector
activation. The co-localization of IRS-2, but not IRS-1, with
tubulin is enhanced upon Taxol-mediated microtubule stabili-
zation, which, in concert with the signaling data, suggests an
interaction of IRS-2 with the microtubule cytoskeleton that
may facilitate its access to effectors such as AKT. Functionally,
IRS-2 sensitizes breast carcinoma cells to apoptotic cell death in
response to treatment with microtubule-disrupting drugs
through amechanism involving the inhibition ofAKT signaling
and regulation of the BH3-only apoptotic activator BIM. Our
Figure 3. Intracellular localization of IRS proteins and co-localization
withmicrotubules.A and B, SUM159 cellswere treatedwith eitherDMSO, 20
M Taxol, or 1M nocodazole (Noc) for 1–2 h before fixation. Fixed cells were
co-stained for IRS-1 or IRS-2 (green) and tubulin (red). Individual images for
IRS-1/IRS-2 and merged IRS/tubulin images are shown (magnification63).
IRS2 signaling to AKT involvesmicrotubules
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data identify IRS-2 as a potential biomarker for the response of
breast cancer patients to Vinca alkaloid drug treatment.
The IRS proteins function as signaling intermediates for both
the IGF-1R and IR. Previous studies have investigated the
importance of the microtubule cytoskeleton in signaling
through the IR in insulin-responsive cell types such as adi-
pocytes and muscle (20, 21). Similar to our findings with
IGF-1R signaling, proximal IR signaling events are not
impacted by microtubule disruption, whereas distal events
such as GLUT4 translocation to the plasma membrane are
inhibited (20). The impact of microtubule disruption on AKT
activation in response to insulin stimulation is cell type-depen-
dent. Insulin-induced AKT activation was modestly reduced in
3T3-L1 adipocytes, maintained in CHO cells that express IR
and IRS-1 (CHO.IR.IRS-1), and inhibited in skeletal muscle
cells upon treatment with microtubule-disrupting drugs (21,
32). Importantly, the involvement of either IRS-1 or IRS-2 was
not investigated in these different cell models. The differential
expression and activation of IRS-1 and IRS-2 in each cell type
may explain the differential responses of these cells tomicrotu-
bule disruption.
Ourdemonstration that IRS-1andIRS-2differ in theirdepen-
dence upon an intact microtubule cytoskeleton for their down-
stream signaling adds to themechanistic understanding of how
signaling by these homologous proteins regulates distinct func-
tional outcomes. IRS-1 and IRS-2 are both capable of recruiting
PI3K and activating AKT, but the functional response to this
activation is quite different for each adaptor protein (1). Stim-
ulation of cells with insulin or IGF-1 promotes proliferation
when IRS-1 is the dominant signaling adaptor (8, 33). Although
a direct role for AKT in this response has not been demon-
strated, it is dependent upon activation of PI3K (33). In con-
trast, stimulation of breast carcinoma cells that express IRS-2 as
the dominant signaling adaptor respond by increasing migra-
tion/invasion and glycolytic metabolism (7–10). IRS-2-depen-
dent activation of PI3K is also required for these cellular
responses (5).With regard tometabolism, the ability of IRS-2 to
selectively regulate distinct downstream AKT effectors con-
tributes to this differential outcome. IRS-2-dependent activa-
tion of AKT results in the phosphorylation and inactivation of
GSK3, and this inactivation is required for IRS-2-mediated reg-
ulation of glucose uptake (5). In this study, expression of the
apoptotic activator BIM increased in response to disruption of
IRS-2-dependent AKT activation, a mechanism that may
involve the selective regulation of another AKT effector path-
way. Specifically, BIM expression is positively regulated by
FOXOtranscriptionfactors,whichareinactivatedbyAKTphos-
phorylation (34–36). IRS-2 has been shownpreviously tomedi-
ate insulin regulation of Foxo1 activity and Bim expression in
neonatal mouse hepatocytes (37).
Our data support the hypothesis that the ability of IRS-2 to
interact with and potentially traffic along microtubules may
determine its access to distinct subsets of effectors to elicit
unique functional responses. Of note, a selective role for IRS-1-
and IRS-2 dependent signaling in skeletal muscle has been
reported that involves differential AKT isoform activation.
Insulin-stimulated myoblast differentiation and glucose meta-
bolism are regulated by IRS-1/AKT2 signaling, whereas signal-
ing through IRS-2/AKT1 controls lipid metabolism (38). The
possibility that AKT isoforms are selectively sensitive tomicro-
tubule disruption could contribute to the differential sensitivity
of IRS-1 and IRS-2 to microtubule loss.
The results of this study are consistent with thework of other
groups that suggests a central role for AKT in the tumor cell
response to microtubule-disrupting drugs (39–41). Specifi-
cally, AKT promotes the phosphorylation of microtubule-
binding proteins that stabilize microtubules and, in doing so,
increases the resistance of tumor cells to drugs that function by
Figure 4. TheRole of IRS-2 in the cellular response tomicrotubuledisruption.A—D, MDA-MB-231 cellswere treatedwithDMSOor the indicateddrugs for
48 h. The cellswere stainedwith propidium iodide and analyzedby flow cytometry. Shownare the percentages of cells in the sub-G1 peak (A and B) or cell cycle
stages (C andD). The data shown represent themean of representative experiments performed three times ( S.E.) (nocodazole, vinblastine, and vinorelbine)
or twice ( S.D.) (Taxol) independently. *, p 0.05 relative to shGFP; **, p 0.01 relative to shGFP.
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disrupting the microtubule cytoskeleton. Our data now reveal
that themechanism bywhich tumor cells regulate AKT activity
will also influence the response to these drugs. Our results have
implications for the use of microtubule-disrupting drugs, such
as vinblastine and vinorelbine, for the treatment of breast can-
cer. The differential responses of IRS-1- and IRS-2-dependent
signaling to these chemotherapeutic drugs raise the possibility
that IRS-2 may influence how breast tumors respond to Vinca
alkaloid drug treatment. We reported previously that expres-
sion of IRS-2 at the cell membrane is associated with a statisti-
cally significant decrease in overall survival in breast cancer
patients (13). We hypothesize that IRS-2 at the cell membrane
is indicative of active signaling, and patients who have tumors
with this staining pattern may be more sensitive to microtu-
bule-disrupting drugs than patients without active IRS-2 sig-
naling. Moreover, breast tumors with low IRS2 expression/
function could be responsive to combination therapies that pair
an AKT inhibitor with a Vinca alkaloid drug. Therefore, IRS-2
could be used as a biomarker to identify patients for targeted
treatment with these drugs.
Experimental procedures
Cell lines, shRNA, and transfection
The MDA-MB-231 cell line was obtained from the ATCC
Cell Biology Collection. SUM-159 cells were a kind gift from
Art Mercurio (UMass Medical School, Worcester, MA). WT,
Irs-1/, and Irs-2/ mammary tumor cell lines were estab-
lished from MMTV-PyV-MT-derived tumors as described
previously (9). Irs-1fl/fl and Irs-2fl/fl mammary tumor cells
were isolated from female FVB MMTV-PyMT::Irs-1fl/fl and
MMTV-PyMT::Irs-2fl/fl mice, respectively, and Irs/ cells
Figure 5. The differential impact of Irs1 and Irs2 on the cellular response to microtubule disruption. A—G, PyMT cells were treated with DMSO or the
indicated drugs for 48 h. The cells were stainedwith propidium iodide and analyzed by flow cytometry. Shown are the percentages of cells in the sub-G1 peak
(A and B) or cell cycle stages (C–G). The data shown represent the mean S.E. of representative experiments performed three times or twice (Taxol;Irs2 cells)
independently. 2fl/fl, PyMT:Irs2fl/fl cells; 2/, PyMT;Irs2/ cells; 2/:IRS2, PyMT:Irs2/:IRS2 cells; 1/, PyMT;Irs1/ cells; 1/:IRS1, PyMT:Irs1/:IRS1
cells. *, p 0.05 relative to Irsfl/fl; **, p 0.001 relative to Irsfl/fl.
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were generated by infection with adenoviral Cre-recombinase
as described previously (5). Lentiviral vectors containing
shRNAs targeting GFP and human IRS-2 were obtained from
Open Biosystems (Huntsville, AL). MDA-MB-231 cells were
infectedwith the virus, and stably expressing cells were selected
by the addition of 2 g/ml puromycin. IRS expression was
restored in Irs/ mammary tumor cells by transfection with
HA-tagged human IRS-1 or IRS-2 (kindly provided by Adrian
Lee, University of Pittsburgh, Pittsburgh, PA) and selection in
G418 (0.5 mg/ml) (11).
Immunoblotting and immunoprecipitation
Cells were either serum-starved overnight (MDA-MB-231)
or for 4 h (PyMT cells) in serum-free medium. Drugs were
added to the medium prior to stimulation with IGF-1. MDA-
MB-231 cellswere treatedwith nocodazole or vinblastine for 30
min and Taxol for 2 h. Themouse tumor cell lines were treated
with nocodazole, vinblastine, or vinorelbine for 1 h. The con-
centrations (see figure legends) and time periods of incubation
were determined to stabilize or disrupt the microtubule cyto-
skeleton, as assessed by immunofluorescence staining for tubu-
lin. For microtubule-altering drugs, paclitaxel (T7402) was
obtained from Sigma-Aldrich (St. Louis, MO), and nocodazole
(S2775), vinblastine (S1248), and vinorelbine (S4269) were
obtained from Selleckchem (Houston, TX). MK2206 (S1078)
was obtained from Selleckchem. Cells were stimulated for 5–30
min with human recombinant IGF-1 (R&D Systems, Minneap-
olis, MN) prior to extraction.
For total cell extract immunoblots, cells were solubilized at
4 °C in radioimmune precipitation assay lysis buffer (25 mM
Tris (pH 8.0), 0.1% sodium dodecyl sulfate, 1% sodium deoxy-
cholate, 1% Nonidet P-40, 150 mM sodium chloride, 10 mM
sodium fluoride, and 1 mM sodium orthovanadate) containing
protease inhibitors (Roche). Cell extracts containing equivalent
amounts of protein were resolved by SDS-PAGE and trans-
ferred to nitrocellulose membranes. The membranes were
blocked for 1 h with a 50 mM Tris buffer (pH 7.5) containing
0.15MNaCl, 0.05%Tween 20, and 5% (w/v) drymilk or 5%BSA,
incubated overnight at 4 °C in the same buffer containing pri-
mary antibodies, and then incubated for 1 h in 5% blocking
buffer with milk containing peroxidase-conjugated secondary
antibodies. Proteins were detected by enhanced chemilumines-
Figure 6. The role of AKT in the IRS-2-dependent response tomicrotubule disruption.MDA-MB-231 cells were treatedwith DMSOor the indicated drugs
for 48 h. A—C, cells were stainedwith propidium iodide and analyzed by flow cytometry. Shown are the percentages of cells in the sub-G1 peak (A) or cell cycle
stages (B and C). The data shown represent themean S.E. of representative experiments performed three times independently. *, p 0.05 relative to shGFP.
D, aliquots of cell extracts containing equivalent amounts of total proteinwere immunoblottedwith antibodies specific for IRS1, IRS2, Ser(P)-473AKT, total AKT,
or tubulin. The data shown in the bottompanel represent themean S.E. of three independent experiments.Noc, nocodazole. *, p 0.05 relative toDMSO; **,
p 0.001 relative to DMSO.
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cence (Bio-Rad, Hercules, CA) using a ChemiDoc XRS (Bio-
Rad) with Image Lab software. Only signals within a linear
range were used for quantitation, and signals were normalized
to total protein and/or housekeeping genes. The following anti-
bodies were used for immunoblotting: IRS-1 (human: C20,
Santa Cruz Biotechnology, Santa Cruz, CA;mouse: Bethyl Cus-
tom Immunochemistry Services), IRS-2 (4502, Cell Signaling
Technology, Danvers, MA), p85 (05-212, Millipore, Billerica,
MA), IGF-1R (3025, Cell Signaling Technology), phospho-
AKT Ser-473 (9271 and 4060, Cell Signaling Technology),
phospho-AKT Thr-308 (2965, Cell Signaling Technology),
AKT (sc-8312, Santa Cruz Biotechnology; 9272, Cell Signaling
Technology),-tubulin (T5168, Sigma-Aldrich), phospho-ERK
(9106, Cell Signaling Technology), ERK (9102, Cell Signaling
Technology), GAPDH (A300-642A, Bethyl), cleaved caspase 3
(9664, Cell Signaling Technology), BIM (2933, Cell Signaling
Technology), peroxidase-conjugated goat anti-rabbit IgG (111-
035-144, Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA), and peroxidase-conjugated goat anti-mouse IgG
(711-035-151, Jackson ImmunoResearch Laboratories, Inc.).
For immunoprecipitations, cells were extracted using a 20
mM Tris (pH 7.4) buffer containing 1% Nonidet P-40, 0.137 M
NaCl, 10% glycerol, 10 mM sodium fluoride, 1 mM sodium
orthovanadate, and protease inhibitors (Roche). Aliquots of cell
extracts containing equivalent amounts of protein were pre-
cleared for 30 min with protein A-Sepharose beads and then
incubated overnight at 4 °C with antibodies and protein A-Sep-
harose beads (Amersham Biosciences, Piscataway, NJ) with
constant agitation. The beads were washed three times in
extraction buffer. Laemmli sample buffer was added to the
samples, and immune complexes were resolved by SDS-
PAGE, transferred to nitrocellulose membranes, and immu-
noblotted as described above. The following antibodies were
used for immunoprecipitation: IRS-1 (C20, Santa Cruz Bio-
technology), IRS-2 (Bethyl Custom Immunochemistry Ser-
vices), IGF-1R (3025, Cell Signaling Technology), rabbit IgG
Figure 7. Involvement of the apoptotic effector BIM in the response to microtubule disruption. A and B, MDA-MB-231 cells were treated with DMSO or
the indicated drugs for 48 h. Aliquots of cell extracts containing equivalent amounts of total protein were immunoblottedwith antibodies specific for cleaved
caspase 3 (A) or BIM (B) and tubulin. The data shown in the bottom panels represent themean S.E. of three independent experiments. *, p 0.05 relative to
DMSO; **, p 0.01 relative to DMSO; #, p 0.05 relative to shGFP-Nocodazole; ##, p 0.01 relative to shGFP-Nocodazole. Noc, nocodazole.
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(sc-2027, Santa Cruz Biotechnology), and mouse IgG2b
(ab18421, Abcam).
Immunofluorescencemicroscopy
Subconfluent, adherent cells plated on glass coverslips were
treated with nocodazole (1M) for 1 h or Taxol (20M) for 2 h.
Cells were washed three timeswithDulbecco’s PBS and fixed in
3.8% paraformaldehyde in Dulbecco’s PBS with 0.5% Tween
(PBST) for 1 h. Permeabilized cells were blocked for 1 h using
3% BSA in PBST. Primary antibodies diluted in blocking buffer
were added to cells and incubated at room temperature for 1 h.
Secondary antibodies were diluted in the same buffer, and cells
were incubated at room temperature for an additional 30 min.
Cells were washed three times with PBST after each antibody
incubation. Coverslips were thenmounted on glass slides using
Prolong Gold containing DAPI (Cell Signaling Technology),
and the slides were viewed by confocal microscopy (Zeiss
LSM700, 63 oil immersion objective). All images were
adjusted equally for brightness/contrast using ImageJ software.
Antibodies used for immunofluorescence included IRS-1
(H165, Santa Cruz Biotechnology), IRS-2 (NB110-57138,
Novus, Littleton, CO), -tubulin (T5168, Sigma-Aldrich),
Alexa Fluor 488 donkey anti-rabbit IgG (A-21206, Thermo
Fisher Scientific, Waltham, MA), and Alexa Fluor 568 donkey
anti-mouse IgG (A10037, Thermo Fisher Scientific). The spec-
ificity of the IRS-1 and IRS-2 antibody staining was validated by
staining PyMT:Irs1/,Irs2/ double-null cells that were
transfected with either empty vector, IRS-1, or IRS-2 (supple-
mental Fig. 1).
Cell cycle analysis
MDA-MB-231 cells were treated with nocodazole (1 M),
vinblastine (20 nM), vinorelbine (20 nM), Taxol (10 M), or
MK2206 (250 nM) for 48 h. Themouse PyMTmammary tumor
cell lines were treated with nocodazole (1 M) or Taxol (1 or 10
M) for 48 h. Adherent cells were collected by trypsinization
after treatment and combinedwith non-adherent cells from the
culture medium for cell cycle analysis. After centrifugation, the
cell pellet was washed once in cold PBS, and the cells were then
fixed in 70% methanol and stored overnight at 20 °C. The
fixed cells were washed once in PBS and then resuspended in
PBS containing 0.1% Triton X-100, 0.1 mM EDTA, 0.05 mg/ml
RNase A (50 units/mg), and 50 g/ml propidium iodide. The
cells were analyzed by flow cytometry using a BD Biosciences
FACSCalibur after 1-h incubation at room temperature.
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Supplemental Figure 1: Validation of IRS1 and IRS2 antibodies.  PyMT:Irs1-/-,Irs2-/- 
double null cells were transfected with either empty vector (pcDNA), HA-IRS1 or HA-IRS2.  
Fixed cells were stained with the indicated IRS1 or IRS2-specific antibodies. Magnification 
63x;  Bar = 20μM
Supplemental Figure 1
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